Site Editor

William J. Gradishar, MD, FACP, FASCO


Heather McArthur, MD, MPH, on Adding Pembrolizumab to Chemotherapy in Early-Stage, High-Risk Breast Cancer

Posted: Tuesday, April 2, 2024

Heather McArthur, MD, MPH, of UT Southwestern Medical Center, discusses her findings from the KEYNOTE-756 trial, which focused on patients with early-stage, high-risk estrogen receptor–positive or HER2-negative breast cancer who may benefit from adding pembrolizumab to neoadjuvant chemotherapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.